- Home
- NCTY vs ADCT Comparison
NCTY vs ADCT Comparison
Compare NCTY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- ADCT
- Stock Information
- Founded
- NCTY 1999
- ADCT 2011
- Country
- NCTY China
- ADCT Switzerland
- Employees
- NCTY N/A
- ADCT N/A
- Industry
- NCTY Business Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- ADCT Health Care
- Exchange
- NCTY Nasdaq
- ADCT Nasdaq
- Market Cap
- NCTY 156.7M
- ADCT 241.0M
- IPO Year
- NCTY 2004
- ADCT 2020
- Fundamental
- Price
- NCTY $9.36
- ADCT $3.09
- Analyst Decision
- NCTY
- ADCT Strong Buy
- Analyst Count
- NCTY 0
- ADCT 5
- Target Price
- NCTY N/A
- ADCT $7.75
- AVG Volume (30 Days)
- NCTY 89.6K
- ADCT 694.8K
- Earning Date
- NCTY 01-01-0001
- ADCT 05-14-2025
- Dividend Yield
- NCTY N/A
- ADCT N/A
- EPS Growth
- NCTY N/A
- ADCT N/A
- EPS
- NCTY N/A
- ADCT N/A
- Revenue
- NCTY $15,305,175.00
- ADCT $75,817,000.00
- Revenue This Year
- NCTY N/A
- ADCT $9.19
- Revenue Next Year
- NCTY N/A
- ADCT $16.27
- P/E Ratio
- NCTY N/A
- ADCT N/A
- Revenue Growth
- NCTY N/A
- ADCT 10.49
- 52 Week Low
- NCTY $5.75
- ADCT $1.05
- 52 Week High
- NCTY $20.59
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- NCTY 32.45
- ADCT 79.62
- Support Level
- NCTY $11.21
- ADCT $1.83
- Resistance Level
- NCTY $11.95
- ADCT $2.35
- Average True Range (ATR)
- NCTY 0.75
- ADCT 0.30
- MACD
- NCTY -0.21
- ADCT 0.13
- Stochastic Oscillator
- NCTY 8.21
- ADCT 98.92
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).